索拉非尼治疗中老年晚期肾癌的疗效观察

Clinical observation of Sorafenib in treatment of middle aged and elderly patients with metastatic renal cell carcinoma

目的研究索拉非尼治疗中老年转移性肾癌（metastatic renal cell carcinoma,mRCC）的长期疗效及安全性。方法回顾性分析解放军总医院2006年10月-2012年4月口服索拉菲尼（Sorafenib）治疗的20例转移性肾癌患者的临床疗效。结果 20例中男性17例,女性3例,中位年龄61（45～83）岁,平均随访时间40个月。其中完全缓解（CR）1例,部分缓解（PR）5例,疾病稳定（SD）14例,至随访截止6例疾病进展（PD）均死亡;客观有效率（objective response rate,ORR）为30%（6/20）,临床获益率（clinical benefit response rate,CBR）指CR＋PR＋SD≥18个月的患者百分比,为65%（13/20）。中位无进展生存期（progression-free-survival,PFS）为46.1（35.8～56.4）个月。结论索拉非尼对中老年晚期肾癌的病情控制理想,长期疗效肯定。

Objective To investigate the effect and safety of Sorafenib in treatment of middle aged and elderly patients with metastatic renal cell carcinoma. Methods Clinical efficacy of Sorafenib in 20 patients diagnosed with metastatic renal cell carcinoma in our hospital from October 2006 to April 2012 were ascertained. Results Of the 20 patients, 17 were male, and 3 were female, with a median age of 61 years（range from 45 to 83 years） and an average follow-up time of 40 months. CR was achieved in 1 case（5.0%）, PR in 5 cases（25.0%）, SD in 14 cases（70.0%）, and PD in 6 cases while these cases were all dead. The objective response rate（ORR） was 30.0%（6/20）, and the clinical benefit response rate（CBR） was 65.0%（13/20）. The progression-free-survival（PFS） was 46.1（95% CI： 35.8-56.4） months. Conclusion There is a favorable efficacy for Sorafenib in treatment of middle aged and elderly patients with metastatic renal cell carcinoma.